@prefix : <http://www.transceleratebiopharmainc.com/LY246708/V1#> .
@prefix pr: <http://www.assero.co.uk/Protocol#> .
@prefix isoC: <http://www.assero.co.uk/ISO11179Concepts#> .
@prefix isoT: <http://www.assero.co.uk/ISO11179Types#> .
@prefix isoR: <http://www.assero.co.uk/ISO11179Registration#> .
@prefix isoI: <http://www.assero.co.uk/ISO11179Identification#> .
@prefix bo: <http://www.assero.co.uk/BusinessOperational#> .
@prefix bc: <http://www.assero.co.uk/BiomedicalConcept#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .

<http://www.transceleratebiopharmainc.com/LY246708/V1>
	rdf:type owl:Ontology ;
.
<http://www.assero.co.uk/EP#82393203-1a00-4014-868c-60d3369e5641>
	rdf:type pr:Epoch ;
	isoC:label "Screening"^^xsd:string ;
	pr:ordinal "1"^^xsd:integer ;
.
<http://www.assero.co.uk/EP#6c4fbee9-9588-4252-bfcf-38eae7643fa0>
	rdf:type pr:Epoch ;
	isoC:label "Treatment"^^xsd:string ;
	pr:ordinal "2"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#00584e58-8d92-4e05-b0d9-ce9650f6c9e6>
	rdf:type pr:Arm ;
	isoC:label "High Dose"^^xsd:string ;
	pr:description "High Dose"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "1"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#883c1418-ecd6-4fdf-ad71-ecbde4ebe620>
	rdf:type pr:Arm ;
	isoC:label "Low Dose"^^xsd:string ;
	pr:description "Low Dose"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "2"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#760722fd-1fdb-44c2-a110-05756f8cf73c>
	rdf:type pr:Arm ;
	isoC:label "Placebo"^^xsd:string ;
	pr:description "Placebo"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "3"^^xsd:integer ;
.
<http://www.assero.co.uk/ELE#b094c55c-3a5f-43cc-8dd8-0e49180ddf3a>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#00584e58-8d92-4e05-b0d9-ce9650f6c9e6> ;
	pr:inEpoch <http://www.assero.co.uk/EP#82393203-1a00-4014-868c-60d3369e5641> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#bd046136-7320-4adc-accc-f00983a22213> ;
.
<http://www.assero.co.uk/ELE#ecbd8614-5913-41d1-b570-7571d55bb003>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#883c1418-ecd6-4fdf-ad71-ecbde4ebe620> ;
	pr:inEpoch <http://www.assero.co.uk/EP#82393203-1a00-4014-868c-60d3369e5641> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#bd046136-7320-4adc-accc-f00983a22213> ;
.
<http://www.assero.co.uk/ELE#9cb8ecf1-530c-44be-a1ab-d566d015afd7>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#760722fd-1fdb-44c2-a110-05756f8cf73c> ;
	pr:inEpoch <http://www.assero.co.uk/EP#82393203-1a00-4014-868c-60d3369e5641> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#bd046136-7320-4adc-accc-f00983a22213> ;
.
<http://www.assero.co.uk/ELE#6a7d92c1-2484-47af-8984-e863cbcc1adb>
	rdf:type pr:Element ;
	isoC:label "High Dose"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#00584e58-8d92-4e05-b0d9-ce9650f6c9e6> ;
	pr:inEpoch <http://www.assero.co.uk/EP#6c4fbee9-9588-4252-bfcf-38eae7643fa0> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#cf7c03e8-bd21-4161-9a15-64c3f11dee76> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#5e98d002-eb19-49e9-8b5a-39a31d5ab914> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#3c4c50d5-219a-4b7c-8607-f39af159ba61> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#159bfb2c-948f-4260-9e4b-14d271196a7d> ;
.
<http://www.assero.co.uk/ELE#126807b3-8ade-4be1-845c-6b02b2834b50>
	rdf:type pr:Element ;
	isoC:label "Low Dose"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#883c1418-ecd6-4fdf-ad71-ecbde4ebe620> ;
	pr:inEpoch <http://www.assero.co.uk/EP#6c4fbee9-9588-4252-bfcf-38eae7643fa0> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#cf7c03e8-bd21-4161-9a15-64c3f11dee76> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#5e98d002-eb19-49e9-8b5a-39a31d5ab914> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#3c4c50d5-219a-4b7c-8607-f39af159ba61> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#159bfb2c-948f-4260-9e4b-14d271196a7d> ;
.
<http://www.assero.co.uk/ELE#de55760c-bf5d-4124-902d-8447d242f4b0>
	rdf:type pr:Element ;
	isoC:label "Placebo"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#760722fd-1fdb-44c2-a110-05756f8cf73c> ;
	pr:inEpoch <http://www.assero.co.uk/EP#6c4fbee9-9588-4252-bfcf-38eae7643fa0> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#cf7c03e8-bd21-4161-9a15-64c3f11dee76> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#5e98d002-eb19-49e9-8b5a-39a31d5ab914> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#3c4c50d5-219a-4b7c-8607-f39af159ba61> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#159bfb2c-948f-4260-9e4b-14d271196a7d> ;
.
:PR
	rdf:type pr:Protocol ;
	isoC:label "LY246708"^^xsd:string ;
	isoT:hasState :PR_RS ;
	isoT:hasIdentifier :PR_SI ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T17:18:58+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "H2Q-MC-LZZT"^^xsd:string ;
	pr:title "Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimerâ€™s Disease."^^xsd:string ;
	pr:shortTitle "LY246708"^^xsd:string ;
	pr:studyPhase :PR_TUC3 ;
	pr:studyType :PR_TUC4 ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_ALZ/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_NSD/V1#TA> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#00584e58-8d92-4e05-b0d9-ce9650f6c9e6> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#883c1418-ecd6-4fdf-ad71-ecbde4ebe620> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#760722fd-1fdb-44c2-a110-05756f8cf73c> ;
	pr:specifiesEpoch <http://www.assero.co.uk/EP#82393203-1a00-4014-868c-60d3369e5641> ;
	pr:specifiesEpoch <http://www.assero.co.uk/EP#6c4fbee9-9588-4252-bfcf-38eae7643fa0> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#fc35378d-de63-4f41-84bb-b112c46880eb> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#5c1f8029-2ee3-4608-b0f5-ca354ebdc175> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#04500453-ae08-4144-bdf4-92f08314fbec> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#8adfd9e0-875a-4d6d-b4a9-1f9dfc3f6c62> ;
.
:PR_RS
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
:PR_SI
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "LY246708"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
:PR_TUC3
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15601> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
:PR_TUC4
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "1"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99076/V55#C99076_C82639> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "2"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66735/V4#C66735_C15228> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "DS8500-A-U202"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/DS8500/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/DS8500/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T17:18:58+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle "DS8500-A-U202"^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/DS8500/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/DS8500/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_DIA/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_M/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "DS8500"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15600> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "CPT_TALib-RA-BWE_V002"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T17:18:58+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle "CPT_TALib-RA-BWE_V002"^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_RA/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_I/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "CPT TALIB RA BWE"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15600> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C16084> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "FLU 001"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T17:18:58+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle "FLU 001"^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_INF/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_V/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "FLU001"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15602> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS>
	rdf:type bc:Assessment ;
	isoC:label "Disability Assessment for Dementia (DAD)"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T17:18:57+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R1> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R2> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R3> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R4> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R5> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R6> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R7> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R8> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R9> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R10> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R11> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "ASS DAD"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R1>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "1"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105183/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R2>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "2"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105181/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R3>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105171/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R4>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105204/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R5>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "5"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105199/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R6>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "6"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105173/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R7>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "7"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105202/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R8>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "8"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105203/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R9>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "9"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105172/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R10>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "10"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105185/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R11>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "11"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105178/V1#BCI> ;
.
<http://www.assero.co.uk/VI#cde782be8b675144b1c3a413d952e5058ca53d38>
	rdf:type pr:Visit ;
	isoC:label "Baseline"^^xsd:string ;
	pr:shortName "BL"^^xsd:string ;
.
<http://www.assero.co.uk/VI#e96a2145277171a0c3f5deddef4f400c2e693123>
	rdf:type pr:Visit ;
	isoC:label "Week 8"^^xsd:string ;
	pr:shortName "Wk8"^^xsd:string ;
.
<http://www.assero.co.uk/VI#4d7196ccd76ee7d4b198c45b837180508d93f61e>
	rdf:type pr:Visit ;
	isoC:label "Week 12"^^xsd:string ;
	pr:shortName "Wk12"^^xsd:string ;
.
<http://www.assero.co.uk/VI#22b0f0c8d6218cbc9e10ab1b91c9e1f800cb4f83>
	rdf:type pr:Visit ;
	isoC:label "Week 16"^^xsd:string ;
	pr:shortName "Wk16"^^xsd:string ;
.
<http://www.assero.co.uk/VI#409a2e79a0b954569269055689ebe4053add5292>
	rdf:type pr:Visit ;
	isoC:label "Week 24"^^xsd:string ;
	pr:shortName "Wk24"^^xsd:string ;
.
<http://www.assero.co.uk/TP#bd046136-7320-4adc-accc-f00983a22213>
	rdf:type pr:Timepoint ;
	isoC:label "TP1"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#5ee6a315-dcdd-4f76-b173-8926f5955dd5> ;
	pr:inVisit <http://www.assero.co.uk/VI#cde782be8b675144b1c3a413d952e5058ca53d38> ;
	pr:hasPlanned <http://www.assero.co.uk/STA#285ec0f7-3735-4a65-978e-4bf9687ebcb7> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#1c7a4cd9-ab23-43bc-bd46-94d2132b8f4f> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#21ae63d1-18c5-4d20-ba1f-8009ecdf69ee> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#8de68cc2-64cd-40fd-8385-4c1f2d6b9152> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#4bf0a7bc-8806-4770-ad7e-10ba64502223> ;
.
<http://www.assero.co.uk/TP#cf7c03e8-bd21-4161-9a15-64c3f11dee76>
	rdf:type pr:Timepoint ;
	isoC:label "TP2"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#b86645db-a0e8-455a-8d77-ae55f305d8fc> ;
	pr:inVisit <http://www.assero.co.uk/VI#e96a2145277171a0c3f5deddef4f400c2e693123> ;
	pr:hasPlanned <http://www.assero.co.uk/STA#97f16f8e-8def-4ae4-b51f-cc5300aee7a8> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#67433513-06c4-4a5a-be35-6881cb42fc73> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#58ff2899-1e0e-4e4a-9af4-aa66bb2ed7ab> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#0c42b4ad-f8f5-4dc6-98cd-17a0513b3fbe> ;
.
<http://www.assero.co.uk/TP#5e98d002-eb19-49e9-8b5a-39a31d5ab914>
	rdf:type pr:Timepoint ;
	isoC:label "TP3"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#fee94195-83c0-4fee-96e1-e30148484280> ;
	pr:inVisit <http://www.assero.co.uk/VI#4d7196ccd76ee7d4b198c45b837180508d93f61e> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#3ada18a2-0864-42b1-97ce-a5736b2edfe8> ;
.
<http://www.assero.co.uk/TP#3c4c50d5-219a-4b7c-8607-f39af159ba61>
	rdf:type pr:Timepoint ;
	isoC:label "TP4"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#1a7f8cb9-5564-4184-ac98-a285a8e3af9a> ;
	pr:inVisit <http://www.assero.co.uk/VI#22b0f0c8d6218cbc9e10ab1b91c9e1f800cb4f83> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#46f37495-adca-40d7-9dac-cc0faa75d4ba> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#1864eff3-fa81-4924-865f-ef452de22c6a> ;
.
<http://www.assero.co.uk/TP#159bfb2c-948f-4260-9e4b-14d271196a7d>
	rdf:type pr:Timepoint ;
	isoC:label "TP5"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#c743fd99-88bb-4e1c-88c6-da380c27b8d1> ;
	pr:inVisit <http://www.assero.co.uk/VI#409a2e79a0b954569269055689ebe4053add5292> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#f6195f28-6605-46d2-87a6-df0871d58c05> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#31446ed6-588f-4c05-8d04-f568af980b8a> ;
.
<http://www.assero.co.uk/IC#5ee6a315-dcdd-4f76-b173-8926f5955dd5>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "0"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#b86645db-a0e8-455a-8d77-ae55f305d8fc>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "4838400"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#fee94195-83c0-4fee-96e1-e30148484280>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "7257600"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#1a7f8cb9-5564-4184-ac98-a285a8e3af9a>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "9676800"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#c743fd99-88bb-4e1c-88c6-da380c27b8d1>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "14515200"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#fc35378d-de63-4f41-84bb-b112c46880eb>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ1"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the effect of Xanomeline Transdermal Therapeutic System (TTS) on the ADAS-Cog and CIBIC+ scores at Week 24 in participants with Mild to Moderate Alzheimerâ€™s Disease"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#a9a96ec019494d5b8b041c1d2468061ae66e35d5> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_1/V1#OB> ;
.
<http://www.assero.co.uk/IC#5c1f8029-2ee3-4608-b0f5-ca354ebdc175>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ2"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#a9a96ec019494d5b8b041c1d2468061ae66e35d5> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_3/V1#OB> ;
.
<http://www.assero.co.uk/IC#04500453-ae08-4144-bdf4-92f08314fbec>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ3"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To document the safety profile of the xanomeline TTS."^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_4/V1#OB> ;
.
<http://www.assero.co.uk/IC#8adfd9e0-875a-4d6d-b4a9-1f9dfc3f6c62>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ4"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the effect of xanomeline TTS on the measure of behavioral/neuropsychiatric symptoms in participants with  Alzheimerâ€™s Disease"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_5/V1#OB> ;
.
<http://www.assero.co.uk/IC#8bdc216c-b9bc-477e-9c22-4177bffa5ea3>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ5"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_6/V1#OB> ;
.
<http://www.assero.co.uk/IC#71b4aec0-07a0-4f05-87fd-e75e17ddbabe>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP1"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8, 16 and 24 in the Alzheimerâ€™s Disease Assessment Scale â€“ Cognitive Assessment (ADAS-Cog) 14 total score"^^xsd:string ;
.
<http://www.assero.co.uk/IC#636d7c0a-583e-438a-a630-e601cb74d9a2>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP2"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8, 16 and 24 in the Clinicianâ€™s Interview-Based Impression of Change plus caregiver input (CIBIC+)"^^xsd:string ;
.
<http://www.assero.co.uk/IC#5e8971e2-f1d1-429b-9267-0cf7cdff2807>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP3"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the Neuropsychiatric Inventory (NPI) total score"^^xsd:string ;
.
<http://www.assero.co.uk/IC#72515757-6bd4-48a9-bd20-5c4a9ffa6c23>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP4"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The proportion of participants with adverse events, serious adverse events (SAEs), and adverse events leading to study intervention discontinuation over the 24-week study intervention period"^^xsd:string ;
.
<http://www.assero.co.uk/IC#ed70861c-ff76-4e6c-a753-045cbca7239c>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP5"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 12 in continuous laboratory tests: Hepatic Function Panel"^^xsd:string ;
.
<http://www.assero.co.uk/IC#dc6fa92e-dbc1-4652-b640-b0a5d6a2f8e4>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP6"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The proportion of participants with abnormal (high or low) laboratory measures (urinalysis) during the postrandomization phase"^^xsd:string ;
.
<http://www.assero.co.uk/IC#0a36cd6b-1d83-4403-99b0-cb72bc5f562a>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP7"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in ECG parameter: QTcF"^^xsd:string ;
.
<http://www.assero.co.uk/IC#06ccdd83-9ae4-4351-825b-af2d88bf417f>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP8"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the Neuropsychiatric Inventory (NPI) total score"^^xsd:string ;
.
<http://www.assero.co.uk/IC#3318ee43-d024-4b6d-ac03-bcb71769c14d>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP9"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the DAD total score"^^xsd:string ;
.
<http://www.assero.co.uk/STA#285ec0f7-3735-4a65-978e-4bf9687ebcb7>
	rdf:type pr:StudyAssessment ;
	isoC:label "Disability Assessment for Dementia (DAD)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS> ;
.
<http://www.assero.co.uk/STA#97f16f8e-8def-4ae4-b51f-cc5300aee7a8>
	rdf:type pr:StudyAssessment ;
	isoC:label "Disability Assessment for Dementia (DAD)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS> ;
.
<http://www.assero.co.uk/STFRM#1c7a4cd9-ab23-43bc-bd46-94d2132b8f4f>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#67433513-06c4-4a5a-be35-6881cb42fc73>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#46f37495-adca-40d7-9dac-cc0faa75d4ba>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#f6195f28-6605-46d2-87a6-df0871d58c05>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#21ae63d1-18c5-4d20-ba1f-8009ecdf69ee>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#58ff2899-1e0e-4e4a-9af4-aa66bb2ed7ab>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#1864eff3-fa81-4924-865f-ef452de22c6a>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#31446ed6-588f-4c05-8d04-f568af980b8a>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#8de68cc2-64cd-40fd-8385-4c1f2d6b9152>
	rdf:type pr:StudyForm ;
	isoC:label "Laboratory Samples"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_LAB_SAMPLES/V1#F> ;
.
<http://www.assero.co.uk/STFRM#3ada18a2-0864-42b1-97ce-a5736b2edfe8>
	rdf:type pr:StudyForm ;
	isoC:label "Laboratory Samples"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_LAB_SAMPLES/V1#F> ;
.
<http://www.assero.co.uk/STFRM#4bf0a7bc-8806-4770-ad7e-10ba64502223>
	rdf:type pr:StudyForm ;
	isoC:label "ECG Measurements"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_ECG/V1#F> ;
.
<http://www.assero.co.uk/STFRM#0c42b4ad-f8f5-4dc6-98cd-17a0513b3fbe>
	rdf:type pr:StudyForm ;
	isoC:label "ECG Measurements"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_ECG/V1#F> ;
.